Cannabis isn't a cure-all and it isn't a punchline. For many conditions the evidence is real and growing. Below is a plain-language snapshot — with sources you can verify yourself.
Informational only — not medical advice. Always talk to a clinician familiar with your situation.
The person who bought this domain in 2010 has Crohn's disease. The pain, the unpredictability, the anxiety, the sleep loss — cannabis took the edge off when nothing else reliably did. That doesn't mean it will work the same for you. It does mean this site won't treat IBD patients as an afterthought.
Patient-reported relief of pain, appetite loss, nausea, and inflammation is consistent across surveys. Small clinical trials have shown symptom improvement and quality-of-life gains, though long-term inflammation outcomes are still being studied.
The National Academies of Sciences (2017) found 'substantial evidence' that cannabis is effective for chronic pain in adults. Often used to reduce opioid reliance.
Decades of evidence support antiemetic effects, including for chemotherapy patients. FDA-approved synthetic cannabinoids (dronabinol, nabilone) exist for this exact use.
Strong evidence that oral cannabinoids reduce patient-reported MS spasticity. Sativex (nabiximols) is approved in many countries.
Epidiolex (purified CBD) is FDA-approved for these rare seizure disorders and has dramatically reduced seizure frequency in many patients.
Many veterans and trauma survivors report sleep and hypervigilance improvements. Clinical research expanding, with several controlled trials underway.
CBD has shown anxiolytic effects in trials. THC effects are dose-dependent — low doses may help, higher doses may worsen anxiety in some.
Mixed but generally positive evidence for short-term sleep onset; long-term effects on sleep architecture less clear.
Strong appetite-stimulating effects well-documented; quality-of-life benefits for patients undergoing aggressive treatment.
Topical cannabinoids show early promise in eczema, psoriasis, and atopic dermatitis. More research needed.
Observational studies report meaningful reductions in frequency and intensity; randomized trials are catching up.
We won't cherry-pick the data. Here are primary sources, mainstream reviews, and active research trackers.